Brought to you by 
KellBenx gets antibodies from AdnaGen for use in prenatal diagnostics
06 Jun 2011
Executive Summary
Alere Inc.’s AdnaGen AG division (biomarkers) has granted KellBenx Inc. (noninvasive prenatal diagnostics for genetic disorders) exclusive rights to antibodies that will be used in the extraction of clinical data from a sample of maternal blood.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
KellBenx gets antibodies from AdnaGen for use in prenatal diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice